Date: 2016-07-12
Type of information: Treatment of the first patient
phase: N/A
Announcement: treatment of the first patient
Company: Atara Biotherapeutics (USA - CA)
Product: EBV-CTL
Action
mechanism: cell therapy/immunotherapy product. Atara's EBV-CTL utilizes a technology in which T-cells are collected from the blood of third-party donors and then exposed to EBV antigens. The resulting activated T-cells are then expanded, characterized, and stored for future therapeutic use in an appropriate partially human leukocyte antigen, or HLA, matched patient, providing an "off-the-shelf", allogeneic, cellular therapeutic option for patients.
Disease: EBV-Associated lymphomas and lymphoproliferative disorders
Therapeutic area: Cancer - Oncology - Transplantation
Country: USA
Trial
details: This multicenter expanded access protocol to provide human leukocyte antigen (HLA) partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV lymphomas or Lymphoproliferative Disorders. Eligible patients have primary or acquired immunodeficiency, and include those that have received allogeneic Hematopoietic Cell Transplants (alloHCT) or Solid Organ Transplants (SOT) and are not eligible for any other trials supporting the development of EBV-CTLs. ( NCT02822495)
Latest
news: * On July 12, 2016, Atara Biotherapeutics announced the dosing of its first patient in the multi-center Expanded Access Protocol (EAP) for Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas and Lymphoproliferative Disorders. This EAP trial is designed to provide continued availability of off-the-shelf allogeneic EBV-CTLs to patients ahead of planned pivotal trials. Two upcoming pivotal trials in patients with rituximab-refractory EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after solid organ transplant (SOT) and hematopoietic cell transplant (HCT) are also on track to begin later this year.
